Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)

Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)

MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA).

Cipla's...

Read more: Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nas...

More Articles …

  1. Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
  2. Marriott International Pilots AI Solutions to Streamline Hotel Design Process for Future Properties in Asia-Pacific
  3. LCM Partners wins two Private Debt Investor 2020 awards
  4. INEOS Styrolution's Zylar 261 used in Samsung's new range of household appliances
  5. Tezos Baking enables Sylo Smart Wallet users to earn rewards from holding XTZ
  6. Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
  7. Nintex Workflow Cloud Helps Zoom Improve Channel Order Process
  8. K7 Computing Launches Lifetime Valid Antivirus - K7 Ultimate Security Infiniti Edition
  9. CORE to open an Australian office to assist Australian entrepreneurs looking to start a business in Hong Kong
  10. TVM Capital Healthcare Exits Cambridge Medical and Rehabilitation Center for US$ 232 Million, a 4.6x Return on Capital Invested